These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37226807)

  • 21. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
    Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
    [No Abstract]   [Full Text] [Related]  

  • 22. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review.
    Farah L; Davaze-Schneider J; Martin T; Nguyen P; Borget I; Martelli N
    Artif Intell Med; 2023 Jun; 140():102547. PubMed ID: 37210155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value and impact of health technology assessment: discussions and recommendations from the 2023 Health Technology Assessment International Global Policy Forum.
    Trowman R; Migliore A; Ollendorf DA
    Int J Technol Assess Health Care; 2023 Dec; 39(1):e75. PubMed ID: 38130164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
    Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
    Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the landscape of health technology assessment in Iran: perspectives from stakeholders on needs, demand and supply.
    Aryankhesal A; Behzadifar M; Bakhtiari A; Shahabi S; Azari S; Darvishi Teli B; Rezapour A; Ehsanzadeh SJ; Behzadifar M
    Health Res Policy Syst; 2024 Jan; 22(1):11. PubMed ID: 38225573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HTA model for laboratory medicine technologies: overview of approaches adopted in some international agencies.
    d'Angela D; Orso M; Migliore A; Polistena B; Spandonaro F; Bernardini S
    Clin Chem Lab Med; 2024 Sep; 62(10):1928-1937. PubMed ID: 39044459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
    Mathes T; Jacobs E; Morfeld JC; Pieper D
    BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model-based study to estimate the health and economic impact of health technology assessment in Thailand.
    Kingkaew P; Budtarad N; Khuntha S; Barlow E; Morton A; Isaranuwatchai W; Teerawattananon Y; Painter C
    Int J Technol Assess Health Care; 2022 May; 38(1):e45. PubMed ID: 35506420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Postma M; Biundo E; Chicoye A; Devlin N; Mark Doherty T; Garcia-Ruiz AJ; Jaros P; Sheikh S; Toumi M; Wasem J; Beck E; Salisbury D; Nolan T
    Vaccine; 2022 Jun; 40(30):3999-4007. PubMed ID: 35597688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. USING EXPERT OPINION IN HEALTH TECHNOLOGY ASSESSMENT: A GUIDELINE REVIEW.
    Hunger T; Schnell-Inderst P; Sahakyan N; Siebert U
    Int J Technol Assess Health Care; 2016 Jan; 32(3):131-9. PubMed ID: 27502308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health technology assessment in Poland and Scotland: comparison of process and decisions.
    Kolasa K; Wasiak R
    Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Spanish Network of Agencies for Health Technology Assessment and Services of the National Health System (RedETS).
    Serrano-Aguilar P; Asua-Batarrita J; Molina-López MT; Espallargues M; Pons-Rafols J; García-Armesto S; Arriola-Bolado P; López-García M; Faraldo-Vallés MJ; Sánchez-Gómez LM; Juárez-Rojo C; Prieto-Yerro I; Casado-Durández P; Sarria-Santamera A
    Int J Technol Assess Health Care; 2019 Jan; 35(3):176-180. PubMed ID: 31006412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".
    Culyer AJ
    Int J Health Policy Manag; 2016 Aug; 5(8):501-505. PubMed ID: 27694664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prioritizing investments in health technology assessment. Can we assess potential value for money?
    Davies L; Drummond M; Papanikolaou P
    Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines.
    Dawkins B; Shinkins B; Ensor T; Jayne D; Meads D
    Int J Technol Assess Health Care; 2024 Nov; 40(1):e59. PubMed ID: 39552285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.